{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:03:19Z","timestamp":1778947399917,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.cpet.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T05:15:17Z","timestamp":1501218917000},"page":"489-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Role of PET\/MR Imaging in Precision Medicine"],"prefix":"10.1016","volume":"12","author":[{"given":"Eugene","family":"Huo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Eisenmenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2017.05.006_bib1","first-page":"3703","article-title":"New strategy for monitoring targeted therapy: molecular imaging","volume":"8","author":"Teng","year":"2013","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00261-016-0894-5","article-title":"An overview of PET\/MR, focused on clinical applications","volume":"42","author":"Catalano","year":"2017","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"10.1016\/j.cpet.2017.05.006_bib3","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2967\/jnumed.111.092726","article-title":"Performance measurements of the Siemens mMR integrated whole-body PET\/MR scanner","volume":"52","author":"Delso","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1148\/radiol.13121038","article-title":"PET\/MR imaging: technical aspects and potential clinical applications","volume":"267","author":"Torigian","year":"2013","journal-title":"Radiology"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2017.05.006_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00259-008-0940-9","article-title":"A\u00a0look ahead: PET\/MR versus PET\/CT","volume":"36","author":"von Schulthess","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2967\/jnumed.111.098608","article-title":"First clinical experience with integrated whole-body PET\/MR: comparison to PET\/CT in patients with oncologic diagnoses","volume":"53","author":"Drzezga","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.113.123547","article-title":"Qualitative and quantitative comparison of PET\/CT and PET\/MR imaging in clinical practice","volume":"55","author":"Al-Nabhani","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2017.05.006_bib8","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1088\/0031-9155\/56\/10\/013","article-title":"Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system","volume":"56","author":"Zaidi","year":"2011","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1148\/radiol.2383041384","article-title":"Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging","volume":"239","author":"Nasu","year":"2006","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1148\/radiol.11110474","article-title":"Whole-body diffusion-weighted MR imaging in cancer: current status and research directions","volume":"261","author":"Padhani","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2017.05.006_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2014.00091","article-title":"The potential role of magnetic resonance spectroscopy in image-guided radiotherapy","volume":"4","author":"Nguyen","year":"2014","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2017.05.006_bib12","first-page":"449","article-title":"Pattern recognition approaches for breast cancer DCE-MRI classification: a systematic review","volume":"36","author":"Fusco","year":"2016","journal-title":"J\u00a0Med Biol Eng"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.semnuclmed.2015.04.002","article-title":"Pitfalls and limitations in simultaneous PET\/MRI","volume":"45","author":"Delso","year":"2015","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1148\/radiol.13130620","article-title":"Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET\/MR and PET\/CT imaging","volume":"268","author":"Chandarana","year":"2013","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2967\/jnumed.114.148056","article-title":"Quantitative PET\/CT\u00a0scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom","volume":"56","author":"Sunderland","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib16","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1118\/1.3455705","article-title":"Variability in PET quantitation within a multicenter consortium","volume":"37","author":"Fahey","year":"2010","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jmr.2003.11.003","article-title":"Image brightening in samples of high dielectric constant","volume":"167","author":"Tropp","year":"2004","journal-title":"J\u00a0Magn Reson"},{"issue":"8","key":"10.1016\/j.cpet.2017.05.006_bib18","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2967\/jnumed.112.116376","article-title":"Systematic evaluation of phantom fluids for simultaneous PET\/MR\u00a0hybrid imaging","volume":"54","author":"Ziegler","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00259-012-2113-0","article-title":"PET\/MR imaging of bone lesions\u2013implications for PET quantification from imperfect attenuation correction","volume":"39","author":"Samarin","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mp.12122","article-title":"Hybrid ZTE\/Dixon MR-based attenuation correction for quantitative uptake estimation of pelvic lesions in PET\/MRI","volume":"44","author":"Leynes","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.cpet.2017.05.006_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/DDDT.S19045","article-title":"Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond","volume":"5","author":"Ou","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00432-011-0976-2","article-title":"Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen","volume":"137","author":"Moon","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"23","key":"10.1016\/j.cpet.2017.05.006_bib23","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2004.00.117","article-title":"Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies","volume":"22","author":"Scartozzi","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","article-title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","volume":"93","author":"Zidan","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.semnuclmed.2015.09.004","article-title":"The potential of metabolic imaging","volume":"46","author":"Di Gialleonardo","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2967\/jnumed.107.045112","article-title":"Current and potential applications of clinical 13C MR spectroscopy","volume":"49","author":"Kurhanewicz","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2017.05.006_bib27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2967\/jnumed.114.141705","article-title":"Hyperpolarized 13C MR for molecular imaging of prostate cancer","volume":"55","author":"Wilson","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib28","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1039\/C3CS60124B","article-title":"Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization","volume":"43","author":"Keshari","year":"2014","journal-title":"Chem Soc Rev"},{"issue":"198","key":"10.1016\/j.cpet.2017.05.006_bib29","doi-asserted-by":"crossref","first-page":"198ra108","DOI":"10.1126\/scitranslmed.3006070","article-title":"Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate","volume":"5","author":"Nelson","year":"2013","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1148\/rg.322115122","article-title":"MR imaging for preoperative evaluation of primary rectal cancer: practical considerations","volume":"32","author":"Kaur","year":"2012","journal-title":"Radiographics"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00261-007-9262-9","article-title":"Preoperative staging of colorectal cancer: CT vs. integrated FDG PET\/CT","volume":"33","author":"Shin","year":"2008","journal-title":"Abdom Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1148\/radiology.182.2.1732979","article-title":"Recurrent rectal cancer and scar: differentiation with PET and MR imaging","volume":"182","author":"Ito","year":"1992","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0006-291X(02)00920-8","article-title":"Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers","volume":"296","author":"Ramirez de Molina","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"10.1016\/j.cpet.2017.05.006_bib34","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinbiochem.2012.08.012","article-title":"The role of choline in prostate cancer","volume":"45","author":"Awwad","year":"2012","journal-title":"Clin Biochem"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib35","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2967\/jnumed.115.170878","article-title":"18F-Choline PET\/MRI: the additional value of PET for MRI-guided transrectal prostate biopsies","volume":"57","author":"Piert","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib36","first-page":"273","article-title":"Comparison of [18F]Fluorocholine and [18F]Fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer","volume":"168","author":"Price","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib37","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/RLU.0b013e3182a77b62","article-title":"False-positive result in 18F-fluorocholine PET\/CT due to incidental and ectopic parathyroid hyperplasia","volume":"39","author":"Cazaentre","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/RLU.0b013e31824c5ffc","article-title":"Incidental finding of parathyroid adenoma with 11C-choline PET\/CT","volume":"37","author":"Mapelli","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2478\/raon-2013-0075","article-title":"Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer","volume":"48","author":"Hodolic","year":"2014","journal-title":"Radiol Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","article-title":"PSMA PET and radionuclide therapy in prostate cancer","volume":"46","author":"Bouchelouche","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/bjs.1800830734","article-title":"Technetium-99m sestamibi parathyroid localization is accurate enough for scan-directed unilateral neck exploration","volume":"83","author":"Borley","year":"1996","journal-title":"Br J Surg"},{"issue":"12","key":"10.1016\/j.cpet.2017.05.006_bib42","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archsurg.135.12.1461","article-title":"Unilateral surgery for primary hyperparathyroidism on the basis of technetium Tc 99m sestamibi and iodine 123 subtraction scanning","volume":"135","author":"Hindie","year":"2000","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib43","first-page":"346","article-title":"The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging","volume":"81","author":"Johnston","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00259-002-0983-2","article-title":"Nuclear medicine and minimally invasive surgery of parathyroid adenomas: a fair marriage","volume":"30","author":"Rubello","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1148\/radiol.13122661","article-title":"How to perform parathyroid 4D CT: tips and traps for technique and interpretation","volume":"270","author":"Hoang","year":"2014","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3174\/ajnr.A3715","article-title":"Prevalence of the polar vessel sign in parathyroid adenomas on the arterial phase of 4D CT","volume":"35","author":"Bahl","year":"2014","journal-title":"AJNR Am J Neuroradiol"},{"issue":"12","key":"10.1016\/j.cpet.2017.05.006_bib47","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/RLU.0000000000000607","article-title":"Localization of parathyroid adenoma by (1)(1)C-choline PET\/CT: preliminary results","volume":"39","author":"Orevi","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib48","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/cen.12681","article-title":"F18-Choline PET\/CT: a novel tool to localize parathyroid adenoma?","volume":"82","author":"van Raalte","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.cpet.2017.05.006_bib49","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00259-014-2837-0","article-title":"(1)(8)F-Fluorocholine PET\/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study","volume":"41","author":"Lezaic","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2431030580","article-title":"Imaging prostate cancer: a multidisciplinary perspective","volume":"243","author":"Hricak","year":"2007","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib51","first-page":"1613","article-title":"Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR","volume":"196","author":"Rosenkrantz","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging - reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/AJR.13.10889","article-title":"Prostate imaging reporting and data system (PI-RADS): reflections on early experience with a standardized interpretation scheme for multiparametric prostate MRI","volume":"202","author":"Westphalen","year":"2014","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.cpet.2017.05.006_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.crad.2016.01.001","article-title":"Predictive value of PI-RADS classification in MRI-directed transrectal ultrasound guided prostate biopsy","volume":"71","author":"NiMhurchu","year":"2016","journal-title":"Clin Radiol"},{"issue":"11\u201312","key":"10.1016\/j.cpet.2017.05.006_bib55","doi-asserted-by":"crossref","first-page":"E377","DOI":"10.5489\/cuaj.3896","article-title":"Relationship between Gleason score and apparent diffusion coefficients of diffusion-weighted magnetic resonance imaging in prostate cancer patients","volume":"10","author":"Kim","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib56","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00330-010-1999-9","article-title":"Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results","volume":"21","author":"Park","year":"2011","journal-title":"Eur Radiol"},{"issue":"Suppl 3","key":"10.1016\/j.cpet.2017.05.006_bib57","doi-asserted-by":"crossref","first-page":"67s","DOI":"10.2967\/jnumed.115.170977","article-title":"Bombesin-targeted PET of prostate cancer","volume":"57","author":"Mansi","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","article-title":"Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer","volume":"46","author":"Kratochwil","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib60","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cpet.2017.05.006_bib61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","article-title":"Comparison of hybrid (68)Ga-PSMA PET\/MRI and (68)Ga-PSMA PET\/CT in the evaluation of lymph node and bone metastases of prostate cancer","volume":"43","author":"Freitag","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2017.05.006_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"10.1016\/j.cpet.2017.05.006_bib63","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2017.05.006_bib64","unstructured":"Molecular Insight Pharmaceuticals I. Study to evaluate 99mTc-MIP-1404 SPECT\/CT imaging in men with biopsy proven low-grade prostate cancer. 2015. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02615067."},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib65","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.cpet.2017.05.006_bib66","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib67","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/cncr.11635","article-title":"Prostate carcinoma presentation, diagnosis, and staging","volume":"98","author":"Miller","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib68","first-page":"1436","article-title":"Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib69","first-page":"540","volume":"177","author":"Cookson","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib70","doi-asserted-by":"crossref","first-page":"e103574","DOI":"10.1371\/journal.pone.0103574","article-title":"Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes","volume":"9","author":"Kwon","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cpet.2017.05.006_bib71","first-page":"910","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib72","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","article-title":"Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib74","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib75","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib76","first-page":"850","article-title":"Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen","volume":"46","author":"Vallabhajosula","year":"2005","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2017.05.006_bib77","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ijc.23529","article-title":"Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study","volume":"123","author":"Hassan","year":"2008","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib78","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1477-2574.2010.00175.x","article-title":"Multimodal management of neuroendocrine liver metastases","volume":"12","author":"Frilling","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cpet.2017.05.006_bib80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0284185113496679","article-title":"Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis","volume":"55","author":"Yang","year":"2014","journal-title":"Acta Radiol"},{"issue":"10","key":"10.1016\/j.cpet.2017.05.006_bib81","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2017.05.006_bib82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40336-016-0193-8","article-title":"Somatostatin receptor PET\/MRI for the evaluation of neuroendocrine tumors","volume":"5","author":"Hope","year":"2017","journal-title":"Clin Transl Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib83","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/RLI.0b013e31828234d0","article-title":"Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography\/magnetic resonance in comparison with positron emission tomography\/computed tomography in patients with neuroendocrine tumors","volume":"48","author":"Gaertner","year":"2013","journal-title":"Invest Radiol"},{"issue":"6","key":"10.1016\/j.cpet.2017.05.006_bib84","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s00261-015-0409-9","article-title":"Simultaneous (68)Ga-DOTA-TOC PET\/MRI with gadoxetate disodium in patients with neuroendocrine tumor","volume":"40","author":"Hope","year":"2015","journal-title":"Abdom Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2017.05.006_bib85","doi-asserted-by":"crossref","first-page":"MT33","DOI":"10.12659\/MSM.882719","volume":"18","author":"Sankowski","year":"2012","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.cpet.2017.05.006_bib86","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1007\/s00330-013-2785-2","article-title":"Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET\/MRI in patients with neuroendocrine tumours of the upper abdomen","volume":"23","author":"Mayerhoefer","year":"2013","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.cpet.2017.05.006_bib87","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/j.ejrad.2011.11.007","article-title":"Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI","volume":"81","author":"Giesel","year":"2012","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib88","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00330-011-2266-4","article-title":"Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours","volume":"22","author":"Schreiter","year":"2012","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.cpet.2017.05.006_bib89","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.ejrad.2015.04.009","article-title":"Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET","volume":"84","author":"Flechsig","year":"2015","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.cpet.2017.05.006_bib90","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","author":"Hofman","year":"2015","journal-title":"Radiographics"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859817300524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859817300524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T22:51:16Z","timestamp":1535583076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859817300524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1556859817300524"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2017.05.006","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of PET\/MR Imaging in Precision Medicine","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}